Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in different applications in the field of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplification by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies. Coronavirus pneumonia (COVID-19) is a serious respiratory infectious disease that has emerged recently. Patients with coronavirus infection demonstrate fever with body temperature exceeding 38 °C, and symptoms, such as dry cough, fatigue, dyspnea, difficulty in breathing, and frosted glass-like symptoms in the lungs 1. The disease is known to be highly transmittable without the occurrence of severe symptoms. The number of cases has reached over tens of millions worldwide. To overcome this pandemic, many researchers have started working on developing a vaccine. However, ongoing vaccine developments are estimated to take over a year before becoming available for public use. As a result, the global clinical community is attempting to repurpose existing drugs to tackle the COVID-19 crisis. Recently, several drugs that can inhibit specific functions of the virus have been proposed and tested as part of the latest clinical treatment approaches. These drugs include chloroquine and hydroxychloroquine. Although the role of these drugs in the treatment of COVID-19 is controversial, hydroxychloroquine is more soluble than chloroquine and produces relatively less toxic metabolites 2-4. Although chloroquine (7-chloro-4-(4-diethylamino-1-methylbutylamino)-quinoline) and hydroxychloroquine (2-[4-[(7-chloroquinolin-4-yl)amino]pentylethylamino]ethanol), which have been in clinical usage for the last seventy years, are drugs for the treatment of autoimmune disease, they are also used as antimalarial drugs. These compounds have recently been reported as potential broad-spectrum antiviral drugs for COVID-19 5 ; however, their benefits against COVID-19 are controversial, with no evident effect on hospitalized patients 6. From a molecular perspective, the...